NDUFS1‐Mediated Mitochondrial Complex I Activity Maintains Pancreatic Cancer Stemness by Promoting PAX2 Hypomethylation

Read full text Summarise with VIRAT
Authors: Xin‐Yu Fan, Wen Li, Yi Shi, Bao‐Qing Xu, Hao Wang, Ruo‐Fei Tian, Zi-Chuan Duan, Jing Fan, Jia‐Rong Liu, Xiu‐Xuan Sun, Bin Wang, Li-Juan Wang
+6 more Ke Wang, Shi‐Jie Wang, Xiang‐Min Yang, Hong‐Yong Cui, Zhi‐Nan Chen, Ling Li
Cited by: 0
References: 56

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ABSTRACT Pancreatic cancer is highly refractory and aggressive, with cancer stem cells (CSCs) being primarily responsible for its metastasis and chemoresistance. Deregulated cellular bioenergetics is a hallmark of cancer cells. However, the influence of bioenergetics on the maintenance of pancreatic CSC stemness and its underlying mechanisms have not been fully elucidated. In this study, pancreatic CSCs, isolated either by sorting ALDH + subpopulation or enriching serially passaged tumorspheres from pancreatic cancer cells and PDX model, exhibited active mitochondrial complex I activity and increased oxidative phosphorylation. Complex I maintains stemness and tumorigenicity through its core subunit, NDUFS1. NDUFS1‐mediated pancreatic CSC stemness is reinforced by high expression of CD147, which promotes pSTAT3 Tyr705 ‐mediated NDUFS1 transcription. To promote stemness, CD147‐NDUFS1 initiates SIRT1‐DNMT1 metaboloepigenetic signaling, decreasing promoter hypomethylation and increasing the mRNA expression of the stem cell transcript factor PAX2 . Moreover, NDUFS1 and CD147 expressions were highly correlated in pancreatic cancer tissues, and their co‐expression was significantly associated with poor patient survival. Taken together, our study provides evidence that mitochondrial complex I functions as a key player in CSC stemness maintenance through NDUFS1‐mediated retrograde metaboloepigenetic signaling. Blocking a key regulator of mitonuclear communication by targeting CD147 may be a novel therapy for pancreatic cancer.

Fields of Study & Subjects

Cancer Cells and Metastasis Cancer Hypoxia and Metabolism Pancreatic and Hepatic Oncology Research

Publication details

Journal / source
MedComm
Volume
7
Issue
4
Pages
e70678–e70678
Publication date
18 March 2026
Language
EN